Stock VTGN VISTAGEN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Official Publications Vistagen Therapeutics, Inc.

Equities

VTGN

US92840H4002

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-22 pm EDT 		5-day change 1st Jan Change
4.78 USD +0.42% Intraday chart for Vistagen Therapeutics, Inc. +0.63% -7.00%
Apr. 01 Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2 CI
Feb. 13 Transcript : Vistagen Therapeutics, Inc., Q3 2024 Earnings Call, Feb 13, 2024

Official Publications

No official publication found

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies
  1. Stock Market
  2. Equities
  3. VTGN Stock
  4. News Vistagen Therapeutics, Inc.
  5. Official Publications